Asian Pacific Journal of Cancer Prevention

  • 제13권11호
  • /
  • Pages.5587-5591
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

A Phase II Study on Continuous Infusional Paclitaxel and 5-Fu as First-line Chemotherapy for Patients with Advanced Esophageal Cancer

  • Gu, Ming (Department of Oncology, Yancheng Hospital, Medical School of Southeast University) ;
  • Li, Su-Yi (Department of Oncology, Zhongda Hospital, Medical School of Southeast University) ;
  • Huang, Xin-En (Department of Chemotherapy, Jiangsu Cancer Hospital & Research Institute) ;
  • Lin, Yan (Department of Oncology, the Second Affiliated Hospital of Nanjing Medical University) ;
  • Cheng, Hong-Yan (Department of Oncology, Zhongda Hospital, Medical School of Southeast University) ;
  • Liu, Lin (Department of Oncology, Zhongda Hospital, Medical School of Southeast University)
  • 발행 : 2012.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: This study was performed to evaluated the efficacy and safety of continuous infusional paclitaxel and 5-Fu as first-line chemotherapy in patients with advanced esophageal squamous cell cancer (ESCC). Methods: A total of 22 patients with advanced esophageal squamous cell cancer with no indications for surgery and radiation therapy, or recurrent patients were enrolled from October 2008 to November 2010. All were treated with PTX 20 $mg/m^2$ was administered through a 16 hours continuous intravenous infusion on days 1 to 3, 8 and 9. DDP 3.75 $mg/m^2$ was given on days 1 to 4 and 8 to 11, continuous infusional 5-FU over 24-hours on days 1 to 5 and 8 to 12 at a dose of 375 $mg/m^2$, and folacin 60 mg orally synchronized with 5-Fu. The treatment was repeated every 21 days for at least two cycles. Results: 22 cases of all enrolled patients could be evaluated for the effect of treatment: 2 cases were CR, 9 cases PR, 5 cases SD and 2 cases PD, giving an overall response rate of 68.2%(15/22). The median time to progression was 7.0 months. The adverse reactions related to chemotherapy were tolerable; the most common toxic effects were marrow depression, alopecia, and fatigue. Conclusion: Low-dose continuous infusional PTX over 16-hours and 5-fu over 24-hours is a promising regimen with good tolerability in treating patients with advanced esophageal squamous cell cancer.

키워드

참고문헌

  1. Al-Batran SE, Ajani JA (2010). Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer, 116, 2511-8.
  2. Bhatt RS, Merchan J, Parker R, et al (2010). A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer, 116, 1751-1756. https://doi.org/10.1002/cncr.24902
  3. Breathnach OS, Georgiadis MS, Schuler BS, et al (2000). Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced nonsmall cell lung cancer. Clin Cancer Res, 6, 2670-6.
  4. Bucci MK, Rosenthal DI, Hershock D, et al (2004). Final report of a pilot trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancer. Am J Clin Oncol, 27, 595-602. https://doi.org/10.1097/01.coc.0000135738.85334.ed
  5. Ekman S, Dreilich M, Lennartsson J, et al (2008). Esophageal cancer: current and emerging therapy modalities. Expert Rev Anticancer Ther, 8, 1433-48. https://doi.org/10.1586/14737140.8.9.1433
  6. Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
  7. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5. https://doi.org/10.7314/APJCP.2012.13.5.1873
  8. Hainsworth JD, Meluch AA, Greco FA, et al (1997). Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial. Semin Oncol, 24, S19-38-S19-42.
  9. Herskovic A, Russell W, Liptay M, et al (2012). Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol, 23, 1095-103. https://doi.org/10.1093/annonc/mdr433
  10. Holmes FA, Valero V, Buzdar AU (1998). Final results: randomized phase III trial of paclitaxel by 3-hour versus 96-hour infusion in patients with metastatic breast cancer: the long and the short of it. Proc Am Soc Clin Oncol, 17, 110a (Abstr 426).
  11. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
  12. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 11, 1059-62.
  13. Kato K, Tahara M, Hironaka S, et al (2011). A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol, 67, 1265-72. https://doi.org/10.1007/s00280-010-1422-x
  14. Langer CJ, Harris J, Horwitz EM, et al (2007). Phase II study of low-dose paclitaxel and cisplatin in combination with splitcourse concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol, 25, 4800-5. https://doi.org/10.1200/JCO.2006.07.9194
  15. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4. https://doi.org/10.7314/APJCP.2012.13.1.301
  16. Li CG, Huang XE,Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
  17. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin(R) administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
  18. Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
  19. Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from Rosa roxburghii Tratt and Fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14. https://doi.org/10.7314/APJCP.2012.13.5.2409
  20. Markman M, Rose PG, Jones E et al (1998). Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer previously failing treatment with 3-hour or 24-hour paclitaxel regimens. J Clin Oncol, 16, 1849-51. https://doi.org/10.1200/JCO.1998.16.5.1849
  21. Mirinezhad SK, Somi MH, Jangjoo AG, et al (2012). Survival rate and prognostic factors of esophageal cancer in east Azerbaijan province, North-west of Iran. Asian Pac J Cancer Prev, 13, 3451-4. https://doi.org/10.7314/APJCP.2012.13.7.3451
  22. Orditura M, Galizia G, Napolitano V, et al(2010) Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study. Cancer Invest, 28, 820-7. https://doi.org/10.3109/07357901003630926
  23. Pasial P, Philippe R (1998). Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol, 16, 301-8. https://doi.org/10.1200/JCO.1998.16.1.301
  24. Polee MB, Eskens FA, van der Burg ME, et al(2002). Phase II study of biweeklyadministration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer, 86, 669-73. https://doi.org/10.1038/sj.bjc.6600166
  25. Seidman AD, Hochhauser D, Gollub M, et al (1996). Ninetysix hour paclitaxel infusion after progression during taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol, 14, 1877-84. https://doi.org/10.1200/JCO.1996.14.6.1877
  26. Shade RJ, Pisters KM, Huber MH, et al (1998-1999). Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs, 16, 237-43.
  27. Socinski MA, Mudd PN, Radomski KM, et al (1998). Phase I trial of a 96-h paclitaxel infusion with filgrastim support in refractory solid tumor patients. Anticancer Drugs, 9, 611-9. https://doi.org/10.1097/00001813-199808000-00006
  28. Socinski MA, Steagall A, Gillenwater H(1999). Second-line chemotherapy with 96-hour infusional paclitaxel I refractory non-small cell lung cancer: report of a Phase II trial. Cancer Invest, 17, 181-8. https://doi.org/10.3109/07357909909021419
  29. Shu J, Li CG, Liu YC, et al (2012). Comparison of serum tumor associated material (TAM) with conventional biomarkers in cancer patients. Asian Pac J Cancer Prev, 13, 2399-403. https://doi.org/10.7314/APJCP.2012.13.5.2399
  30. Wang T, Zhang SF, Wang L (2010). A 24-hour continuous infusion of paclitaxel in the treatment of advanced esophageal cancer. Nat Med J China, 90, 1986-8.
  31. West HL, Crowley JJ, Vance RB, et al(2005). Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714) : a Southwest Oncology Group study. Ann Oncol, 16, 1076-80. https://doi.org/10.1093/annonc/mdi215
  32. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
  33. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
  34. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar(R) combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
  35. Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54. https://doi.org/10.7314/APJCP.2012.13.5.2349
  36. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
  37. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
  38. Yu DS, Huang XE, Zhou JN, et al (2012). Comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40. https://doi.org/10.7314/APJCP.2012.13.5.2339
  39. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
  40. Zhang XZ, Huang XE, Xu YL, et al (2012). A phase II study on voriconazole in treating chinese patients with malignant hematological disorder and invasive aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8. https://doi.org/10.7314/APJCP.2012.13.5.2415
  41. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.

피인용 문헌

  1. ) Combined with Three-dimensional Conformal External Beam Radiotherapy in Treating Patients with Inoperable Esophageal Cancer vol.13, pp.12, 2012, https://doi.org/10.7314/APJCP.2012.13.12.6523
  2. Helicobacter pylori Infection and the Risk of Colorectal Adenoma and Adenocarcinoma: an Updated Meta-analysis of Different Testing Methods vol.14, pp.12, 2013, https://doi.org/10.7314/APJCP.2013.14.12.7613
  3. Phase II Study on Breast Conservative Surgery Plus Chemo- and Radiotherapy in Treating Chinese Patients with Early Staged Breast Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3747
  4. Potential Therapeutic Efficacy of Curcumin in Liver Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3855
  5. Hsa-miR-181a-5p Expression and Effects on Cell Proliferation in Gastric Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3871
  6. Acidic Pelvic Drainage as a Predictive Factor For Anastomotic Leakage after Surgery for Patients with Rectal Cancer vol.14, pp.9, 2013, https://doi.org/10.7314/APJCP.2013.14.9.5441
  7. Efficacy of Taxane-Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5493
  8. Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3581
  9. Infiltration of Alternatively Activated Macrophages in Cancer Tissue Is Associated with MDSC and Th2 Polarization in Patients with Esophageal Cancer vol.9, pp.8, 2014, https://doi.org/10.1371/journal.pone.0104453